News
NICE does not recommend Leqembi (lecanemab) for early Alzheimer's disease
NICE (UK): In draft guidance, the NICE stated that the limited benefits of lecanemab, do not justify its costs, citing not just the price of the treatment but the related expenses of administering it and monitoring for side effects
Condition: Alzheimers
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins